Novo Nordisk launched a Phase 3 clinical trial for an oral version of its obesity treatment, Wegovy. The study evaluates lower doses of oral semaglutide to determine the minimal effective amount for weight loss in overweight or obese adults. This initiative aims to improve patient compliance and broaden drug accessibility through expanded dosing options.
Novo Nordisk also restructured its China operations to expand its leadership in the obesity care market. This reorganization merges the diabetes and insulin divisions into a single unit. The company created an additional division for emerging channels to better align with market demands. These strategic moves focus on maximizing product reach across major global markets.